MARÍA DOLORES
CABALLERO BARRIGÓN
Investigadora en el periodo 1998-2022
Claude Bernard University Lyon 1
Villeurbanne, FranciaPublicaciones en colaboración con investigadores/as de Claude Bernard University Lyon 1 (9)
2019
-
Pembrolizumab in relapsed or refractory primary mediastinal large b-cell lymphoma
Journal of Clinical Oncology
2018
-
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204
-
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
The Lancet Haematology, Vol. 5, Núm. 8, pp. e359-e367
2017
-
Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
Journal of Clinical Oncology, Vol. 35, Núm. 22, pp. 2473-2481
2016
-
Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial
Journal of Clinical Oncology, Vol. 34, Núm. 22, pp. 2575-2582
2014
-
Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma
Blood
-
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma
Cancer Treatment Reviews, Vol. 40, Núm. 9, pp. 1080-1088
2013
-
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
Haematologica, Vol. 98, Núm. 3, pp. 357-363